explore -WSS

explore

author：focus 2025-10-02 23:48:31 - browse：84

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： ReNAgade cuts staff seven months after raising $300 million

WSS

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Rep. Raul Ruiz on the physician shortage and more

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Sen. Bill Cassidy on how to lower drug prices

knowledge

explore

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

Heart attack and stroke risk calculators need revising

What to know about a major upcoming Wegovy heart health study

Medicare details structure of new drug price negotiation program

J&J to emphasize cancer drugs, stop much of its vaccine research

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

歪道道，科技媒体人，互联网分析师。

Dobbs anniversary: the lost opportunity of abortion as health care

Trump seeks lengthy delay of classified docs trial, citing upcoming election

hotspot

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Fetal surgery at risk from Dobbs and new abortion restrictions

Pediatric cancer treatments threatened by a new FDA policy

Rep. Raul Ruiz on the physician shortage and more

Despite FDA concern, risk that CAR

With clinical trial data readouts, here's how to spot spin

focus

leisure time

leisure time

explore